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 4
Imagination is more important than knowledge. 
For knowledge is limited to all we now know and 
understand, while imagination embraces the entire 
world, and all there ever will be to know and 
understand. 
 
Albert Einstein (1879-1955) 
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1. General introduction 
 
1.1 Cardiovascular complications in inflammatory rheumatic 
diseases
Inflammatory rheumatic diseases (IRD) are associated with various cardiovascular 
manifestations, including peri-, myo-, and endocarditis, valvular abnormalities, heart failure, 
arrhythmias, aortic aneurysms, arterial and pulmonary hypertension, thromboembolism, 
amyloidosis, vasculitis, and atherosclerosis (Figure 1) (1;2).  
 
Figure 1. Cardiac and vascular manifestations in rheumatic diseases 
 
© Cleveland Clinic 2008  
All rights reserved. Reproduced with permission. 
Cleveland Clinic | 9500 Euclid Avenue | Cleveland, OH 44195 | 216.444.2200 | 800.223.2273  
 
 
1.1.1 Coronary artery disease in inflammatory rheumatic diseases 
Coronary artery disease (CAD), predominantly caused by atherothrombosis, is a leading 
cause of mortality in both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) 
(3-10). In RA, that affects 0.5% of population, most of the observed standardized mortality 
ratios for cardiovascular death range between 1.13 and 5.15, depending on the selected patient 
population (10). The cardiovascular risk is increased also in young individuals; Bjornadal et 
al. found a 5.5 –fold increase in the risk for cardiovascular death in 20-39 year old women 
with RA compared to women without RA (11). In RA, CAD is often unrecognized and thus, 
undertreated (12-15). Acute coronary syndromes in RA are more frequent and more severe, 
associated with higher relapse and mortality rates, than observed in the general population 
(12;16). Patients with SLE are 5-10 times more likely to experience a coronary event than the 
average individual in the healthy general population (7). Esdaile et al. estimated a 17-fold 
higher risk of mortality secondary to CAD in SLE compared to the general population (17). 
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Manzi et al. demonstrated a 50-fold higher risk of a myocardial infarction in women 35 to 44 
years old with SLE compared to women without SLE (18).   
Although cardiovascular research in rheumatology has focused mainly on RA and SLE, 
there is increasing evidence that other IRDs, including primary vasculitides, antiphospholipid 
syndrome, and gout, may be associated with accelerated atherothrombosis (4;19-21). In a 
study on Pima Indians with unspecified arthritis, a 2-fold increase in cardiovascular mortality 
was found in those with two or more swollen joints compared to those with no swollen joints 
(22). 
Cardiovascular morbidity in IRD is related to traditional cardiovascular risk factors, 
medication side effects, and the activity and severity of the rheumatic disease (8;9;23;24). 
There are indications that effective antirheumatic treatment may lower cardiovascular risk 
(4;25-29). 
 
1.1.2 Cardiac involvement in spondyloarthritides 
It has long been known that spondyloarthritides are associated with cardiovascular 
comorbidities related to HLA-B27 genotype, inflammation, and disease duration (30;31). The 
most characteristic complications are aortic root and valve disease and conduction disorders 
caused by a sclerosing inflammatory process involving small arteries (obliterative 
endarteritis) (31-33). Aortic valve and root involvement have been detected in ankylosing 
spondylitis in more than 50% of patients by echocardiography, and in up to 100% of patients 
in autopsy studies (31;34). The most common valvular disorder in spondyloarthritides is 
aortic insufficiency, caused by aortic root dilatation and/or cusp pathology.  
Although CAD morbidity is increased in autoimmune diseases, only a few studies have 
addressed this topic in the spondyloarthritides (35). However, some studies indicate a 
proatherogenic risk profile and an excess of endothelial damage and/or atherosclerosis in 
patients with ankylosing spondylitis and psoriasis/psoriatic arthritis (30;35;36;36;37;37-
41;41-44). Caliskan et al. found a reduction in the coronary flow reserve in 
spondyloarthritides, indicating impaired macro- and/or microvascular cardiac circulation (45). 
The coronary flow reserve was independently related to systemic inflammatory biomarkers. 
1.2 Causes of vascular lumen narrowing 
CAD is mainly caused by a narrowing of a vascular lumen, usually due to atherosclerosis. 
The narrowing may be also caused by other pathologies, including thromboembolism, 
vasospasm, aneurysms, and vasculitis, which imply different follow up and treatment 
procedures (Figure 2). However, due to limited diagnostic tools, it may be difficult or 
impossible to distinguish these conditions from each other.  
 
Figure 2. Causes of vascular lumen narrowing 
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1.2.1 Aortic and cardiac vasculitis 
Cardiac ischemia may be caused by vasculitis in the epicardial coronary arteries, in small 
cardiac vessels, and/or in the aorta, when the inflammation affects the outlets of coronary 
arteries (Figure 3). An aortic inflammation may also result in formation of aortic aneurysms 
or stenoses, and aortic valve failure.  
 
Figure 3. Sites of vascular stenoses that may cause myocardial ischemia 
 
© Cleveland Clinic 2008. All rights reserved. Reproduced with permission. 
Cleveland Clinic | 9500 Euclid Avenue | Cleveland, OH 44195 | 216.444.2200 | 800.223.2273  
The true prevalence of aortitis and cardiac vasculitis is uncertain due to the limited 
diagnostic tools and the small number of studies that have addressed the topic. Furthermore, 
the criteria for histological diagnosis of vasculitis and their interpretation may vary between 
the studies, and contribute to variations in the results.  
Aortitis and cardiac vasculitis occur in various rheumatic and other conditions (32;46-54). 
Aortitis has been described in primary vasculitides (Takayasu’s arteritis, GCA [giant cell 
arteritis], Kawasaki disease, ANCA associated vasculitides, hypersensitivity vasculitis, 
Behcet’s disease, Cogan’s disease), RA, spondyloarthritides, juvenile idiopathic arthritis, 
polymyalgia rheumatica, SLE, relapsing polychondritis, infections (e.g. syphilis), sarcoidosis, 
and malignancies. In addition, aortitis may manifest as an idiopathic, single-organ condition. 
The clinical significance of isolated aortitis, and therefore, its optimal treatment and follow 
up, is not clear (52;55). The pathology of aortitis is frequently non-specific, contributing little 
to differential diagnosis. Giant cells, for example, that typically occur in GCA and Takayasu’s 
arteritis, can also occur in other rheumatic diseases and non-rheumatic conditions (including 
idiopathic inflammatory aneurysms and sarcoidosis) (32).  
According to available studies, aortic and cardiac vasculitis appear to occur in IRDs more 
frequently than commonly assumed in clinical practice. For example, an autopsy study 
revealed cardiac vasculitis in 17 (10%) of 169 consecutive RA subjects, and 10 of those 17 
experienced myocardial infarctions (56). Another autopsy series of 188 RA patients identified 
10 patients with aortitis, of which three died as a direct result of aortitis and four others of a 
Epicardial coronary 
arteries 
Aorta at the outlets of 
coronary arteries 
Small intramural arteries, 
arterioles and capillaries 
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myocardial infarction secondary to vasculitis. Typically, the diagnosis was not made before 
death (57). Up to 30-50% of RA patients have subclinical aortic abnormalities on 
echocardiography, but the clinical significance of this finding is unclear (32). In an X-ray 
study of RA patients, enlargement of the aortic root predicted a higher risk of mortality (58). 
Vasculitis in the aorta and its large branches is increasingly considered to be a feature of 
GCA (59) (Figure 4). A study using fluorodeoxyglucose-positron emission tomography 
(FDG-PET) revealed aortic inflammation in >50% of GCA patients (60).  
1.2.2 Diagnostic challenges in detecting aortic and cardiac vasculitis 
Vasculitis is a potentially life-threatening condition, treatable with immunosuppression. 
Because immunosuppressive treatment may cause serious side effects, the diagnosis should be 
accurate. Unfortunately, tools for detecting aortitis are limited, and it is almost impossible to 
diagnose cardiac small vessel vasculitis and coronaritis antemortem. These conditions have 
therefore been commonly unrecognized and undertreated, and knowledge about their 
prognosis and optimal treatment is also limited. Many cases were not diagnosed until 
performing an autopsy. Ischemic symptoms of aortitis are unspecific, and systemic symptoms 
of inflammation are not always present (52;53). Elevated levels of acute-phase reactants, 
including C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR), are not 
pathognomonic. In addition, in active vasculitides, these levels may be within a normal range. 
Angiography provides anatomic information about stenoses and aneurysms, but does not 
distinguish between etiologies. The types of lumen changes and the fluctuations observed on 
repeated examinations may evoke a suspicion of vasculitis for some patients, but the 
specificity is low.  
Serial imaging by magnetic resonance angiography with edema-weighted images may 
reveal wall thickening or “edema”, but these findings do not always indicate active 
inflammation (49;61). Fluorodeoxyglucose-positron emission tomography (FDG-PET) is a 
sensitive method for demonstrating large vessel vasculitis, but is not suitable for detecting 
areas smaller than 3-4 mm in diameter (62) (Figure 4). Also other novel imaging modalities, 
including intravascular ultrasound, might be useful in detecting vasculitis. However, the 
usefulness of intravascular ultrasound is limited, because it is an invasive and expensive 
procedure. The gold standard for diagnosing vasculitis is histology, but obtaining actual 
specimens from living patients is extremely challenging. Although collecting vascular 
specimens from coronary endarterectomies is possible, the specimens do not contain the 
whole vessel wall; thus, their usefulness is primarily limited to studies of the components of 
atherosclerotic lesions. Myocardial biopsies are associated with a risk for complications, and 
they likely have low sensitivity due to the small tissue samples. Histological examination of 
the aorta in living patients has been performed primarily with specimens from surgery for 
aortic valvular disorders or aneurysms. However, this approach is probably seldom helpful in 
clinical practice because these surgeries are performed only in a relative small number of 
patients, and clinicians are likely to overlook this diagnostic opportunity. 
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Figure 4. FDG-PET scan in giant cell arteritis 
 
 
 
FDG-PET scan showing FDG uptake in thoracoabdominal aorta as well as subclavian, 
axillary, carotid and iliac arteries of a patient with GCA, indicating a widespread vascular 
inflammation. (Courtesy of Thorsten A. Bley.) 
 
 
1.3 Links between atherosclerosis and inflammation 
Atherosclerosis is an inflammatory disease (63;64). Atherosclerotic lesions contain 
inflammatory cells (predominantly T cells and macrophages) that appear to contribute to 
plaque formation and destabilization. Destabilization of plaques leads to their rupture and 
consequent thrombosis, representing a crucial pathomechanism in acute coronary syndromes 
(Figures 2 and 5).  
In addition to inflammation in vascular lesions, signs of persistent low-grade systemic 
inflammation are associated with atherosclerosis. Levels of systemic inflammatory 
biomarkers, including CRP and Tumor Necrosis Factor – alpha (TNF alpha), are related to the 
severity of cardiovascular disease, and predict future cardiovascular events in patients with 
cardiovascular disease and in an apparently healthy population (65;66). Even small 
differences in CRP levels, measured by high-sensitivity assays, rather than conventional 
methods, appear to be significant (67). The role of systemic inflammation in atherosclerosis 
has not been fully elucidated. Systemic inflammatory mediators may be secondary to the 
inflammatory process in atherosclerotic lesions, and/or underlying cardiovascular risk factors 
(smoking, hypertension, or obesity) (63). Systemic inflammatory biomarkers may also 
promote atherothrombosis. For example, proinflammatory cytokines, including TNF alpha, 
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IL-1beta, or IL-6, induce dyslipidemia, insulin resistance, prothrombotic status, endothelial 
dysfunction, and oxidative stress (enhancing the oxidation of LDL to the highly 
proatherogenic ox-LDL) (66;67).  
 
Figure 5. The morphology of rupture-prone and ruptured atherosclerotic plaques 
Top left panel illustrates a rupture-prone plaque. The lipid-rich core occupies approximately 
40% of the plaque area and contains multiple cholesterol crystals. The fibrous cap is thin and 
inflamed with few smooth muscle cells. Plaque microvessels originating from the adventitia 
extend through the media into the base of the plaque, and the plaque tends to grow outwards 
(expansive remodelling). Top right panel illustrates the thin and locally weakened fibrous 
cap. Macrophages are abundantly present whereas smooth muscle cells are scarce. Bottom 
left panel illustrates the corresponding ruptured plaque with consequent thrombus covering 
the rupture site. (Reproduced with permission from Thim et al. J Intern Med. 2008;263:506-
16.) 
 
 
It has been suggested that the pathologies of IRD and atherosclerosis might share some 
inflammatory and immunologic pathways (4;29;68). In fact, the inflammatory/immunologic 
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response in atherosclerosis is surprisingly similar to that in RA (69;70); for example, TNF 
alpha and IL-6 play important roles in both conditions. In addition, a clonal expansion of 
CD4+CD28- cells has been observed in the peripheral blood of patients with RA and those 
with acute coronary syndrome, but not healthy individuals. CD4+CD28- cells have been also 
found in rheumatoid synovitis and unstable atherosclerotic lesions. These senescent T cells 
lack the co-stimulatory CD28 molecule, and exhibit features of natural killer cells with highly 
proinflammatory properties (29;70;71). Similarities in the pathogenesis of RA and 
atherosclerosis are highlighted by some common risk factors, including smoking.  
Because cardiovascular morbidity is increased in various disorders associated with chronic 
inflammation, including autoimmune diseases, chronic infections, diabetes mellitus, 
depression and obesity, a causal relationship between chronic inflammation and 
cardiovascular disease has been suggested (4). Indeed, the features of inflammatory processes 
differ among the respective diseases. For example, in contrast to many other inflammatory 
conditions, CRP levels usually remain low during active SLE. Nevertheless, chronic 
inflammatory conditions are likely to share some important common pathways that might 
play a crucial role in premature atherothrombosis; e.g., defects in immunocompetent cells, 
metabolic effects of chronic inflammation, and/or endothelial injury/vascular inflammation 
(4;21). 
Although insights into the inflammatory response in atherosclerosis are rapidly being 
revealed, and several candidate antigens have been identified, the precise mechanism 
underlying atherosclerosis is still unclear. Several studies have proposed roles for infections 
(e.g. cytomegalovirus, Chlamydia pneumonia, or pathogen burden) and autoimmunity (72-
75). Atherosclerosis is associated with the occurrence of several autoantibodies, including 
antibodies to oxidized low density lipoprotein, antibodies to beta 2 glycoprotein I, antibodies 
to heat shock proteins, and antibodies to endothelial cells. According to the “Response-to-
Injury” hypothesis, atherosclerosis may be caused by vascular injury induced by various 
factors, such as pressure, chemical substances, infections, etc. (69). 
 
1.4 Resistance to atherosclerosis in different vessels 
Blood vessels have different susceptibilities to atherosclerosis. Veins, for example, are 
usually less vulnerable than arteries. However, differences exist also within the arterial tree 
(76;77). For example, the internal mammary artery (IMA), though similar in dimension to the 
coronary arteries, is highly protected from atherosclerosis (78). The risk for vascular stenosis 
remains low even when the IMA is used for a coronary graft; IMA conduits have longer 
patency than other donor vessels, including the saphenous vein (79-81).  
In theory, differences in the prevalence of atherosclerosis in different vessels may be due to 
regional vascular properties, pressure, and/or intraluminal rheologic properties that determine 
susceptibility to injury and inflammation (82).  
 
1.5 The driving force behind the study
The journey of this project started at a course of autoimmune diseases for rheumatologists. 
A cardiologist stressed the points that vasculitis was a potential cause of CAD in rheumatic 
diseases, and that a different therapeutic approach was needed for cardiac vasculitis versus 
atherosclerosis. However, he was not able to answer the question of how these two conditions 
can be distinguished. Therefore, we started to look for diagnostic tools that could demonstrate 
cardiac vasculitis by tissue examination. We focused on the potential of taking biopsies 
during coronary artery bypass grafting (CABG), because it is a relatively common form of 
cardiac surgery. We were not able to perform coronary artery biopsies due to the high risk it 
posed for patients, but we found a safe way to collect aortic and cardiac tissue (containing 
small cardiac vessels). At that point, we became aware of the challenges involved in the 
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interpretation of histological criteria for vasculitis (see General discussion). Therefore, we 
decided to evaluate vascular inflammation in a descriptive manner rather than distinguish 
between vasculitis and non-vasculitis.  
In addition to vasculitis, we were interested in the mechanisms that promote atherosclerosis 
in IRD. While most research concerns the importance of traditional cardiovascular risk factors 
and circulating inflammatory mediators, we focused on finding clues directly in the vascular 
tissue. We hypothesized that patients with IRD might be prone to vascular inflammation 
(including low-grade forms) that might promote plaque formation and/or destabilization. The 
susceptibilities of different types of vessels to inflammation might explain differences in their 
vulnerabilities to atherosclerosis.  
We were frequently asked by our colleagues whether patients with different IRDs 
underwent CABG earlier than patients without IRD, because it might indicate an earlier debut 
of severe CAD in the respective IRDs. Because relatively little research has addressed the role 
of CAD in spondyloarthritides, we were particularly interested in the age of patients with 
spondyloarthritis.  
To identify factors that might play a role in the pathogenesis of cardiovascular disease and 
assess their importance, we wanted to established a comprehensive long term data- and 
biobank containing biological material and information about patients with and without CAD. 
These grounds gave rise to the aims for our study.  
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2. Main hypotheses and aims
2.1 Hypotheses 
 Aortic inflammation might be detectable in tissue specimens removed during CABG. 
 Local vascular inflammation in any vascular layer might, in some cases, lead to formation 
of atherosclerotic lesions and/or to their destabilization. 
 Vascular inflammation, including that localized outside atherosclerotic lesions, might be 
more common and pronounced in patients with IRD compared to those without IRD, and 
contribute to the high cardiovascular risk in IRD.
 The susceptibilities of different types of vessels to inflammation might underlie 
differences in their vulnerabilities to atherosclerosis. 
 Patients with spondyloarthritides have premature CAD, and therefore undergo a first 
CABG earlier than those without spondyloarthritides. 
 
2.2 Purpose 
We wanted to extend the knowledge regarding the existence and features of vascular 
inflammation. In addition, we aimed to identify a diagnostic tool for aortic inflammation and 
indicators of premature CAD in spondyloarthritides. 
 
2.3 Aims
 To determine whether aortic specimens obtained during CABG would be suitable for 
detecting aortic inflammation.  
 To compare the occurrence and extent of inflammatory cell infiltrates in the aorta of CAD 
patients with and without IRD.  
 To compare vessels with different susceptibilities to atherosclerosis (aorta, saphenous 
vein, IMA) for the occurrence of mononuclear cell infiltrates outside of atherosclerotic 
lesions. 
 To look for predictors of vascular inflammatory infiltrates in non-atherosclerotic areas. 
 To examine whether patients with spondyloarthritis underwent a first CABG at a younger 
age than those without spondyloarthritis.  
 To establish a research data- and biobank for future studies. 
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3. Methods 
In this chapter, I describe only the cross-sectional part of the study discussed in Papers I-III. 
However, we have planned a follow up of the CABG groups to assess the outcomes. 
 
3.1 Patients
 
3.1.1 Patient groups described in Papers I and II 
 
CAD patients with IRD (CAD-IRD group, n=70) 
The inclusion into the Feiring Heart Biopsy Study began in 2001. We planned to include all 
patients with IRD that had been referred to CABG at the Feiring Heart Clinic and the 
University Hospital of North Norway, Tromsø. However, only one patient (with RA) was 
enrolled in Tromsø. All the other subjects were consecutively enrolled at the Feiring Heart 
Clinic, where all subjects referred for CABG between May 2001 and January 2005 were 
actively screened for rheumatic diseases (due to I. Hollan’s illness, no patients underwent 
biopsies between July 2004 and January 2005). The rheumatologic diagnosis was based on 
clinical examination performed by one physician (I. Hollan), a review of medical records, and 
previous X-ray images. 
Out of 116 patients with verified IRD, 70 were enrolled into the biopsy study (Figure 6): 
three patients refused to undergo biopsies, and 43 did not undergo biopsies due to I. Hollan’s 
absence or preoperative time constraints. The inclusion criteria were age >18 years; referred 
to CABG surgery due to CAD; confirmed IRD according to accepted diagnostic criteria (83-
88) and absence of any clinically significant infection or malignancy. In Paper I, we described 
patients in whom aortic specimens were taken (66 IRD patients and 51 controls), and in Paper 
II, patients in whom saphenous vein or IMA specimens had been taken (65 IRD and 51 
control patients) (Figure 6).  
 
CAD patients without IRD (CAD-nonIRD group, n=53)  
The CAD-nonIRD group was consecutively included at the Feiring Heart Clinic during the 
same period of time as the CAD-IRD group, and was matched to the CAD-IRD group for age 
and sex at a group level. The inclusion criteria were age >18 years; referred to CABG surgery 
due to CAD; absence of IRD, psoriasis, clinically significant infection, and malignancy.  
Figure 6. Patients included for examination by biopsies in the Feiring Heart Study 
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3.1.2 Patient groups described in Paper III 
 
Spondyloarthritis patients undergoing a first CABG (SpA group, n=30) 
Of the patients with IRD that had been referred to CABG at the Feiring Heart Clinic 
(screened as described for the CAD-IRD group), we selected those with spondyloarthritis 
undergoing a first CABG between May 2001 and January 2005. This group included 15 with 
ankylosing spondylitis, 14 with psoriatic arthritis, and 1 with Reiter’s disease.  
The AS was diagnosed in accordance with the 1984 modified New York criteria (15), and 
psoriatic arthritis with the Moll and Wright criteria (16). The patient with reactive arthritis 
disease had had oligoarthritis, conjunctivitis, and aseptic urethritis 20 years prior to the 
CABG.  
 
Patients without spondyloarthritis undergoing a first CABG (non-SpA group, n=3822) 
In this group, we selected patients not included in the SpA group that underwent a first 
CABG at the same clinic during the same period of time as the SpA group.  
 
3.1.3 Other patient groups (biobank) 
 
Healthy controls (n=30) 
Healthy volunteers were recruited among the staff of Lillehammer Hospital for Rheumatic 
Diseases and their acquaintances in 2004. The inclusion criteria were absence of clinically 
significant disease, trauma, or surgery during the preceding 6 weeks; absence of pregnancy, 
alcohol, and drug abuse; age in the same range as patients in the CAD-IRD group. The group 
was matched to CAD-IRD for sex at a group level. 
 
RA patients without cardiovascular complications (n=30) 
This group was consecutively included at the Lillehammer Hospital for Rheumatic diseases 
between 2007 and 2008. The inclusion criteria were RA confirmed according to the American 
College of Rheumatology 1987 criteria (83); absence of cardiovascular disease (judged by 
medical history, clinical findings, and electrocardiographic findings); absence of clinically 
significant chronic infection or malignancy; not pregnant; absence of clinically significant 
acute infection, trauma, or surgery during the preceding 6 weeks; within the same age range 
as the RA patients from the CAD-IRD group. The group was matched to the subgroup of RA 
patients in the CAD-IRD group for sex at a group level.  
3.2 Data collection 
 
3.2.1 CAD-IRD and CAD-nonIRD groups  
These groups were preoperatively examined by interview, self-reported questionnaires, 
physical examination, ankle brachial index, and blood tests. During the CABG, several tissue 
specimens were collected, and the surgeons recorded the macroscopic findings.  
 
Medical history and physical findings 
Dr. Hollan performed all physical examinations (including assessments of the disease 
severity and activity of IRD), and recorded all demographic data, detailed medical history 
(including angiographic findings), and information on treatments. The data were recorded in a 
predefined form, using questions requiring “yes” or “no” or other predefined answers 
whenever applicable. The onset of IRD was defined as the date of diagnosis by a physician. A 
positive family history of CAD was defined as CAD in first-degree relatives at ages< 65 years 
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old. Hypercholesterolemia was defined as a total s-cholesterol>5.5 mmol/l recorded in the 
patient’s medical records or current use of lipid-lowering drugs. Significant coronary stenosis 
was defined as a diameter reduction>50% by visual estimate. Left ventricular hypertrophy 
was diagnosed by electrocardiography and/or echocardiography. Left ventricle ejection 
fraction was determined by ventriculography.  
Biopsies
We collected tissue from the aorta and saphenous vein that was routinely removed during a 
CABG. In addition, we collected several other specimens in a manner that did not increase the 
complication risk. 
 
Figure 7. Coronary artery bypass grafts 
 
© Feiringklinikken 2008.  
All rights reserved. Reproduced with permission. 
 
Biopsy procedures 
 Aorta (Figure 7): We collected tissue that was removed for the establishment of an 
aortocoronary anastomoses. Subsequently, part of the adventitia (up to 10×25 mm) 
covered by the epicardium was removed from the ventral part of the ascending aorta, and 
one to three punch holes (each 4.8 mm in diameter) were made through the vessel wall for 
proximal aortocoronary anastomoses in the same area. The punch specimens consisted of 
the intima and media, and sometimes a thin layer of the adventitia. To avoid 
thromboembolic complications, the aortic specimens were taken from areas with less 
pronounced gross signs of atherosclerosis. In two patients that underwent repair of an 
aortic aneurysm during CABG, specimens were collected from the edge of the aortic 
operational incision. 
 Saphenous vein: We collected the excess portion of the prepared saphenous vein (up to 
several centimetres) that remained after venous grafting was performed.  
 IMA: We removed a 5-10 mm-long specimen from the IMA, distal to the surgical cut.  
Area for taking aortic biopsies 
Internal mammary artery graft 
Venous graft 
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 Right atrium: Biopsies from the right atrium (up to 3×2 mm) were obtained from a 10-20 
mm long incision that was routinely performed during CABG for insertion of a cannula 
for extracorporeal circulation.  
 Rectus abdominis muscle: Biopsies from the rectus abdominis muscle (ca. 5×5×3 mm) 
were taken from the incision in the thorax. 
 Skin: Two 4×2 mm skin specimens were collected from surgical cuts: one from the 
thorax, and one from the leg.  
 Cardiac valves: In patients that had cardiac valve replacement surgery in addition to 
CABG, the removed valvular tissue was collected. 
 
All specimens were collected and treated according to a detailed protocol. The specimens 
were divided into small portions: some were fixed in formalin and embedded in paraffin; 
others were snap-frozen in liquid nitrogen, and stored at –75oC. To simplify the biopsy 
assessment procedure, we stored only frozen aortic specimens (not paraffin fixed specimens) 
in eight patients. However, because the frozen sections were lower quality for histological 
examination, we used paraffin sections in the remaining patients. Nevertheless, both the 
frozen and paraffin fixed specimens were suitable for demonstrating inflammatory cell 
infiltrates. For histological analyses, we selected one 3-m thick section from the aortic 
adventitial tissue (specimen A), one from an aortic punch specimen (specimen B), one from 
the IMA, and one from the saphenous vein.  
The sections were stained with hematoxylin, eosin, and saffron. Two experts, blinded to the 
clinical data, examined the sections by light microscopy in random order for the presence and 
location of atherosclerotic lesions, inflammatory cell infiltrates, and other signs of vasculitis, 
including giant cells, granuloma, leucocytoclasis, and necrosis of the vessel wall. When the 
two interpretations were discordant, an additional reading was performed by a third expert to 
adjudicate the findings.  
Atherosclerotic lesions were defined according to “A Definition of Advanced Types of 
Atherosclerotic Lesions and a Histological Classification of Atherosclerosis” (American Heart 
Association) (89), and calcifications in the intima of the saphenous vein were considered 
atherosclerotic plaques.  
To our knowledge, no similar studies had previously been performed; thus, we established a 
new scoring system for the inflammatory cell infiltrates. In the aortic adventitia, we 
distinguished between the inflammatory infiltrates adjacent to the epicardium and those in the 
inner adventitia (in case they had different causes and different clinical significance) (Figure 
8).  
There is no clear anatomic border between the epicardial and adventitial loose connective 
tissues; thus, the differentiation was based on the pathologists’ judgment. Inflammatory 
infiltrates adjacent to the epicardial mesothelium were classified as epicardial 
(submesothelial), unless there was diffuse spreading into the inner adventitia. Infiltrates freely 
localized in the adventitia and large epicardial infiltrates that diffusely spread into the 
adventitia were considered adventitial. Submesothelial mononuclear cell infiltrates (MCIs) 
were scored as follows: 0= no infiltration, 1= mild infiltration, and 2= pronounced infiltration. 
MCIs in the inner adventitia were semiquantified as follows: 0= no infiltrates, 1= 1–3 
infiltrates, and 2= 3 infiltrates or diffuse infiltration. The size of the largest infiltrate in a 
single section was classified according to the number of mononuclear cells, where 0= none, 
1= 3–49 cells, 2= 50–99 cells, 3= 100–199 cells, and 4= 200 cells. IMA specimens were also 
examined for the presence of inflammatory cell infiltrates in the perivascular tissue. In 
addition, a single evaluation was performed to determine the intima/media ratio (1 or >1) 
and intimal thickening (yes/no) in the IMA and saphenous vein. The sizes of MCIs in the 
saphenous vein were semi-quantified (>50 inflammatory cells per infiltrate: yes/no).  
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The surgeons recorded gross signs of inflammation, defined as redness, induration, or 
edema of the vessel wall (yes/no), and the presence of atherosclerotic plaques (yes/no) in the 
aorta. They also evaluated gross signs of inflammation in the saphenous vein and the IMA 
and the quality of the venous conduit (good, medium, or poor).  
 
Figure 8. Assessment of the aortic specimens 
 
 
 
We investigated the presence and location of atherosclerotic lesions and inflammatory cell 
infiltrates. We semi-quantified the number of inflammatory cell infiltrates and the size of the 
largest infiltrate per section. 
 
 
Blood samples 
Blood samples were collected preoperatively for biochemical, hematological, 
immunological, and microbiological tests. Routine biochemical and hematological tests were 
performed consecutively. For most analyses, multiple small portions of serum, EDTA, and 
citrate from plasma and whole blood were stored in a freezer at –75oC to be analyzed in 
batches. 
 
3.2.2 Healthy controls and RA patients without cardiovascular 
complications
These groups were examined by blood tests. In addition, the RA patients were given a 
rheumatologic examination and self-reported questionnaires, similar to those given to the 
CAD-IRD group.  
 
3.2.3 Non-SpA group 
In this group, demographic and clinical data from medical records were recorded. The use 
of non-steroidal anti-inflammatory drugs (NSAIDs) and coxibs was recorded only in a 
random sample of 84 control patients. 
 
Tunica intima
Tunica adventitia 
Tunica media 
Inflammatory cell  
infiltrate 
Atherosclerotic 
plaque 
Mesothelium 
Vasa vasorum 
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3.3 Ethics 
The Regional Ethics Committee for Medical Research approved the study protocol. The 
data- and biobank has approval until 2018. The Norwegian Directorate for Health and Social 
Affairs approved specimen analysis in specified laboratories in foreign countries. 
 
3.4 Statistics
We used the chi-square and Fisher’s exact tests to assess differences in proportions in 
independent samples, and McNemar’s test to assess differences in proportions in two related 
samples (for example, the occurrence of pathologies in two different arteries from the same 
individual).  
The independent sample t-test and Mann-Whitney U test were used to examine differences 
in continuous variables in two independent samples.  
Logistic regression analyses were used to identify predictors of vascular mononuclear cell 
infiltrates (MCIs) and of vascular MCIs50 cells. Due to the small sample size of our study, 
we built the logistic regression models using clinical judgment. For simple analyses, we 
selected independent variables that might have a logical relationship to the chosen dependent 
variables (MCIs and MCIs50), including variables reflecting disease severity, activity, and 
duration of rheumatic disease and CAD; cardiovascular risk factors; treatment; coexisting 
atherosclerosis; CRP; ESR; and demographic data. Crucial variables (age and gender) and 
variables that had p<0.10 in the simple analyses were used further in the multiple logistic 
regression models (Papers I and II). 
To identify predictors of the age at CABG, we used linear regression analyses. The 
selection of independent variables for these analyses was again based on clinical judgment. 
Because we wanted to compare the effects of spondyloarthritis and traditional cardiovascular 
risk factors on the age at first CABG, we used the spondyloarthritis diagnosis and the 
traditional cardiovascular risk factors as independent variables in multiple linear regression, 
model I. In a second linear regression, model II, we examined whether the effect of these 
factors were independent of current systemic glucocorticosteroid treatment. Preceding the 
multiple regression modeling, we performed simple regression analyses for all the mentioned 
independent variables. 
The analyses were performed with SPSS for Windows, version 14-15 (SPSS Inc, Chicago, 
IL). The level of statistical significance was set at 0.05, and all statistical tests were two-sided.  
 
 25
4. Summary of results 
 
4.1 Paper I 
Aortic specimens were obtained in 66 IRD and 51 non-IRD patients; aortic punch 
specimens were obtained in 64 IRD and all the non-IRD patients; and aortic adventitia 
specimens were obtained in 63 IRD and 44 non-IRD patients. The patient characteristics are 
described in Paper I, Table 1. The IRD group comprised patients with RA (n=23), psoriatic 
arthritis (n=10), undifferentiated seronegative arthritis (n=1), SLE (n=3), ankylosing 
spondylitis (n=6), Reiter’s disease (n=1), GCA (n=6), polymyalgia rheumatica (n=14), 
primary Sjögren’s syndrome (n=1), and undifferentiated collagenosis (n=1).  
Acute inflammatory infiltrates in the aorta occurred in one control patient (in the 
adventitia). Atherosclerotic lesions were present in 21% of IRD and 14% of non-IRD patients 
(p=0.35). MCIs within atherosclerotic lesions occurred in 5% of IRD and 6% of non-IRD 
patients (p=0.69). Epicardial MCIs occurred in 48% of IRD and 51% of non-IRD patients 
(p=0.78). Medial MCIs were present in 10% of IRD and no non-IRD patients (p=0.035); they 
were found only in patients that also had adventitial MCIs. Adventitial MCIs occurred in 30 
of 64 (47%) IRD and 10 of 51 (20%) non-IRD patients (odds ratio=3.6, p=0.002, 95%CI: 1.6-
8.5). The adventitial MCIs in IRD patients were likely to be larger and more numerous than 
those in non-IRD patients. Adventitial MCIs were present in most of the examined rheumatic 
diagnoses, and they were especially pronounced in patients with GCA/polymyalgia 
rheumatica or spondyloarthritis. 
Of the examined clinical parameters, only IRD and current cigarette smoking independently 
predicted the occurrence and size of adventitial MCIs in adjusted analyses.  
IRD and non-IRD patients with adventitial MCIs had higher CRP levels then those without 
adventitial MCIs. Adventitial MCIs were observed in a higher proportion of patients with 
unstable, compared to those with stable, atherosclerotic lesions (67% vs. 17%). However, 
none of these differences were statistically significant.  
Patients with RA, spondyloarthritis, or GCA/polymyalgia rheumatica that used systemic 
glucocorticosteroids showed a trend towards a lower prevalence and size of adventitial MCIs 
(statistically non significant). The difference in the prevalence of adventitial MCIs in 
glucocorticosteroid users and non-users almost reached statistical significance in the RA 
subgroup (p=0.051). Among patients with RA, psoriatic arthritis, or undifferentiated arthritis, 
adventitial MCIs were observed in 2 of 8 (25%) patients treated with methotrexate, neither of 
2 (0%) patients treated with TNF alpha inhibitors, 6 of 9 (67%) patients treated with other 
disease modifying antirheumatic drugs, and 6 of 14 (43%) patients not currently receiving 
disease modifying antirheumatic drugs (p=0.20). 
One non-IRD and 3 IRD patients had undergone abdominal aneurysm repair and 3 IRD 
patients had a thoracic aneurysm. All patients with thoracic aneurysms had MCIs in the media 
and adventitia, and 3 of 4 patients with a history of abdominal aneurysm had adventitial 
MCIs. Medial and adventitial MCIs in the 7 patients with current or former aortic aneurysms 
were significantly more frequent than in patients without aortic aneurysms (p=0.003 and 
p=0.007, respectively).  
The MCIs in non-atherosclerotic areas were localized around the vasa vasorum and/or 
throughout the connective tissue. They consisted mainly of lymphocytes, with a marked 
involvement of plasma cells in some patients (Figure 10). Giant cells were observed in 
adventitial MCIs in one patient with psoriatic arthritis. No leucocytoclasis, granuloma, or 
vessel wall necrosis was observed in any specimen. 
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Aortic inflammation was clinically silent in all patients. The surgeon’s gross assessment of 
aortic inflammation had a low positive predictive value (0.30), but a high negative predictive 
value (0.90) for adventitial MCIs.  
  
4.2 Paper II 
We examined 65 IRD and 51 non-IRD patients from the Feiring Heart Biopsy Study that 
had specimens taken from the saphenous vein and/or the IMA (Figure 6). Patient 
characteristics are described in Paper II, Table 1. All but one patient, in whom an aortic 
specimen was not obtained, were part of the patient population from Paper I. Saphenous vein 
specimens were available in 106 patients, IMA specimens in 103 patients (however, the IMA 
was observed in only 96 of these specimens), and aortic specimens in 115 patients.  
MCIs in the vascular media and/or adventitia were present in the saphenous vein in 18 of 
106 subjects (17%), in the IMA in 2 of 96 subjects (2%), and in the aorta in 40 of 115 subjects 
(35%). In this chapter, we focus mainly on findings in the saphenous vein and the IMA 
because findings in the aorta were thoroughly described in Paper I. The medial and adventitial 
MCIs in the saphenous vein and IMA consisted mainly of lymphocytes localized around the 
vasa vasorum and/or diffusely in connective tissue, often at the junction between the media 
and adventitia (Figure 10). No acute inflammatory infiltrates, giant cells, granulomas, 
leucocytoclasis, or necroses of the vessel walls were found in any venous or IMA specimens.  
We did not observe any significant relationships between the occurrences of MCIs in the 
aorta, saphenous vein, and IMA when they occurred in a single individual. Current cigarette 
smoking and IRD were independent predictors of the occurrences of medial or adventitial 
MCIs in the aorta, but not in the saphenous vein or IMA.  
Atherosclerotic lesions were observed in 3 of 106 (3%) saphenous vein specimens (from 
IRD patients) and no IMA specimens (Figure 9). Thickening and fibrosis of the saphenous 
vein vessel wall was common, and intimal thickening in the saphenous vein was more 
pronounced than in the IMA.  
Seven of 96 patients had inflammation in fatty and/or muscular tissue around the IMA.   
Gross examination by surgeons did not reveal inflammation in any saphenous vein or IMA 
specimens. The gross quality of venous conduits was similar in the IRD and non-IRD groups, 
and was not related to the occurrence of MCI in the saphenous vein.  
Figure 9. Occurrence of atherosclerotic lesions and mononuclear cell infiltrates in non-
atherosclerotic areas of the aorta, saphenous vein and internal mammary artery (%) 
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Figure 10. Light microscopy of the aorta, saphenous vein, and internal mammary artery 
(haematoxylin and eosin stain)
1)      2)  
   
3)      4) 
   
5)      6) 
    
1) A large MCI in the inner aortic adventitia of a patient with giant cell arteritis (GCA) that 
underwent repair of an ascending aortic aneurysm during the CABG operation. The patient 
also had perivascular MCIs in the media and an atherosclerotic plaque in the intima. The 
inflammatory changes in the deep vascular layers may have been secondary, but also 
primary, to atherosclerosis and/or aneurysm (100×). 2) High-power view of the adventitia 
from the specimen shown in 1 (400×). 3) Pronounced MCI in the aortic adventitia with 
fibrosis in a patient with GCA (40×). 4) MCI in the aortic media of the patient shown in 3 
(400×). 5) Pronounced diffuse submesothelial MCIs in the aortic specimen of a patient with 
RA and thoracic aneurysm. MCIs spread diffusely into the inner adventitia and were also 
present in the media (100×). 6) High-power view of the adventitia from the specimen shown 
in 5 (400×).  
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7)        8) 
     
9)        10) 
     
11)         12) 
     
7) MCI in the inner part of the aortic adventitia of a patient with ankylosing spondylitis that 
also had a MCI in the media (400×). 8) MCI in the inner aortic adventitia of a patient with 
psoriatic arthritis (400×). 9) Small MCI in the inner aortic adventitia of a control patient 
(400×). 10) Spread aortic submesothelial MCI, not considered to affect the inner adventitia, 
in a patient with polymyalgia rheumatica (100×). 11) MCIs in the saphenous vein of a patient 
with psoriatic arthritis (400×). 12) MCI in the internal mammary artery of a control patient 
(400×).  
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4.3 Paper III 
Of the patients undergoing a first CABG, 30 (0.78%; 95% CI: 0.50-1.06) had CAD with 
spondyloarthritides (SpA group) and 3822 had CAD alone (non-SpA group). We did not find 
any statistically significant differences in the frequency of a concomitant aortic or cardiac 
valve surgery or in the distribution of traditional cardiovascular risk factors between the SpA 
and non-SpA groups. The mean ages (SD) of patients with and without spondyloarthritides 
were 60±9 and 67±10 years, respectively (p<0.001). 53% of patients with spondyloarthritis 
and 25% of patients without spondyloarthritis were <60 years old. Patients with ankylosing 
spondylitis had a mean age of 58±10 years, and patients with psoriatic arthritis had a mean 
age of 62±7 years (p=0.15).  
Patients with spondyloarthritides had fewer coronary arteries with significant stenoses 
compared to the non-SpA group (2.50.6 vs. 2.70.5, respectively; p=0.025). However, 60% 
of patients with spondyloarthritis versus 52% of patients without spondyloarthritis had 
previously sustained a myocardial infarction (p=0.4). Most of the other cardiovascular 
prognostic factors, including the left ventricle ejection fraction, class of the New York Heart 
Association Functional Classification (NYHA), left main coronary artery stenosis, left 
ventricle hypertrophy, occurrence and the mean number of previous myocardial infarctions, 
were more altered in the SpA than in the non-SpA patients, but the differences were not 
statistically significant. Use of lipid lowering drugs, ACE inhibitors, and betablockers was 
similar in both groups, but patients with spondyloarthritis were more likely to use 
acetylsalicylic acid (p=0.046) and systemic glucocorticosteroids (p=0.012) then the control 
patients. Most control patients used systemic glucocorticosteroids due to a chronic obstructive 
pulmonary disease/asthma, or due to autoimmune diseases. 
We used two multiple linear regression models to look for predictors of age at the first 
CABG (Table 1). In the first model, we adjusted for traditional cardiovascular risk factors and 
a spondyloarthritis diagnosis. In the second model, we also adjusted for use of systemic 
glucocorticosteroids. The results from both models were consistent. Spondyloarthritis was a 
stronger predictor of early CABG than most of the examined cardiovascular risk factors; only 
current cigarette smoking had a similar effect. Also male sex, hypercholesterolemia, positive 
family history of CAD, higher body mass index, absence of hypertension, and absence of 
glucocorticosteroid treatment correlated with a lower mean age at the first CABG. Non-
insulin-dependent diabetes and former smoking had no effect on the mean age at the first 
CABG. Separate analyses of the ankylosing spondylitis and psoriatic arthritis subgroups 
showed similar results to those found for the whole SpA group.  
Use of NSAIDs or coxibs had no significant effect on the age at the first CABG. The age at 
spondyloarthritis onset correlated positively with the age at the first CABG (beta = 0.33, p = 
0.005, 95%CI: 0.11-0.55, r2 = 0.239). 
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Table 1. Predictors of age at the first CABG – results from 2 multiple linear regression 
models (n=3852)* 
Age at the first CABG 
Model I† Model II‡ 
Beta (95% CI) p Beta (95% CI) P 
Spondyloarthritis -6.2 (-9.5, -2.8) <0.001 -6.6 (-9.9, -3.3) <0.001
Female sex  4.8 (4.1, 5.5) <0.001  4.7 (4.0, 5.4) <0.001
BMI -0.05 (-0.07, -0.03) <0.001 -0.05 (-0,07, -0.03)  <0.001
Hypercholesterolemia -4.2 (-5.0, -3.4) <0.001 -4.2 (-5.0, -3.4) <0.001
Hypertension  0.9 (0.3, 1.5) 0.005  0.9 (0.3, 1.5) 0.004 
DM-insulin -1.4 (-2.7, -0.1) 0.033 -1.5 (-2.7,-0.2) 0.022 
DM-oral antidiabetics  0.5 (-0.6, 1.6) 0.368  0.5 (-0.6, 1.6) 0.391 
DM-diet -0.3 (-2.0, 1.2) 0.674 -0.4 (-2.0, 1.2) 0.608 
Current smoking -5.7 (-6.5, -5.0) <0.001 -5.7 (-6.5,-5.0) <0.001
Former smoking -0.5 (-1.2, 0.2) 0.149 -0.5 (-1.2, 0.1) 0.122 
Family history of CAD -2.6 (-3.3, -2.0) <0.001 -2.6 (-3.2,-2.0) <0.001
Systemic glucocorticosteroids    4.8 (3.1, 6.5) <0.001
*CABG = coronary artery bypass graft surgery. BMI = body mass index. CAD= coronary 
artery disease. DM insulin = diabetes mellitus treated with insulin. DM-oral antidiabetics = 
DM treated with oral antidiabetics. DM-diet = DM treated with diet. 
†Model I: adjusted for spondyloarthritis, sex, BMI, hypercholesterolemia, hypertension, 
DM-diet, DM-oral antidiabetics, DM-insulin, current smoking, former smoking, and family 
history of CAD (r2= 0.16).  
‡Model II: adjusted for the same factors as Model I and for current systemic 
glucocorticosteroid treatment (r2= 0.17). 
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5. General discussion 
 
5.1 Methodological aspects 
It is important to interpret the statistically significant as well as non-significant results with 
caution. As in any study, our findings may be accidental or influenced by biases and 
confounding factors; thus, further research is needed for validation.  
 
5.1.1 Study design 
The part of the study described in Papers I-III has a cross-sectional design. Cross-sectional 
studies do not allow the determination of causal relationships. On the other hand, they tend to 
be easier and more rapidly completed than other forms of observational studies, and may 
therefore generate hypotheses in a feasible way.  
To minimize the role of potential confounding factors, we chose a controlled matched 
design, and adjusted statistical analyses for possible confounders. Indeed, a complete 
exclusion of any confounder is impossible because there may be some unknown factors and 
some may not be detectable in a study. In addition, statistical analyses may not allow control 
of all potential confounders, e.g., due to a small sample size. All these sources of uncertainty 
may play a role in our study.  
 
5.1.2 Patients  
We wished to examine as large a population as feasible of patients that required a CABG. 
Therefore, we originally planned to include patients at two or several centers of cardiothoracic 
surgery. However, there were many practical challenges in running the project: the screening, 
examination, and treatment of the blood and tissue samples were time consuming, and some 
parts of this process were difficult to integrate into the tight program of preoperative 
procedures. In addition, it was necessary to maintain close, flexible cooperation between the 
cardiologist and rheumatologist. As the only physician involved in the rheumatologic 
examination, I was required to travel to the clinic to examine the patients. Therefore, despite a 
positive attitude at other centers, we enrolled all but one patient at the Feiring Heart Clinic, 
which was closest to my place of residence. We interrupted the inclusion of patients into the 
CAD groups after approximately 4 years, when, due to illness, I was not able to visit the 
Feiring Heart Clinic (it is over 100 kilometers from my residence).  
At the Feiring Heart Clinic, we collected biological specimens in 70 out of 107 IRD 
patients that underwent CABG between May 2001 and July 2004. We were not able to 
include all 107 patients mainly due to a short hospitalization time before the CABG. Often, 
there was little time (frequently outside of ordinary working hours) to examine the patient and 
obtain the necessary medical information to confirm an IRD diagnosis. Furthermore, the study 
tasks were given a lower priority than the necessary preoperative procedures. In addition, in 
spite of our active approach, we might have overlooked some few IRD cases because the 
screening might be underprioritized in some circumstances, e.g. in critically diseased patients.  
Due to the logistic problems, the number of patients was relatively small. Thus, the lack of 
statistical significance in some results might be caused by type 2 errors that may have masked 
true differences. However, the study remains useful because it extends the limited available 
cellular and molecular data that describe vascular processes underlying accelerated 
atherosclerosis in IRD. To our knowledge, this is the only study of its kind, and our findings 
may provide important information for guiding further research. Compared to other studies on 
surgical vascular specimens in IRD, our sample size is still relatively large (90). In addition, 
the study population is well characterized, and a variety of biological specimens from each 
patient was gathered. Thus, it is possible to analyze the relationships between various tissue 
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and circulatory biomarkers in individual patients. Another strength of the study was the large 
size of the non-SpA control group.  
A potential drawback of this study is that we lumped together patients with different IRDs 
that have different disease mechanisms. However, chronic inflammatory conditions may share 
some common mechanisms that contribute to premature atherosclerosis, and vascular 
inflammation might be one such mechanism. Furthermore, our approach enabled the 
demonstration of trends in different diagnostic subsets. Because the subgroups were too small 
to draw definitive conclusions, larger studies of homogenous diagnostic subgroups are 
needed. However, obtaining aortic surgical specimens from large numbers of CAD patients 
with the particular rheumatic diseases will probably be extremely difficult as the IRDs are 
rare, low numbers of these patients undergo CABG, and the logistics in collecting specimens 
during cardiovascular surgery are challenging. By our approach, we were able to provide 
information about the trends in the whole IRD group as well as in the respective diagnostic 
subgroups. However, we acknowledge that similar vascular changes could be caused by 
different inflammatory mechanisms, and this could not be demonstrated in this study. 
We based most of the IRD diagnoses on relatively strict criteria, which enabled a lucid 
definition of the IRD population. However, we therefore could not provide information about 
vascular pathologies in patients with earlier and milder forms of the diseases involved. Also, 
the non-SpA group might have contained patients with spondyloarthritides that did not meet 
the criteria for spondyloarthritis. This might cause an underestimation of the differences 
between the rheumatic and control patients. The non-SpA group also comprised patients with 
other inflammatory conditions, e.g. autoimmune diseases, infections, obesity, or diabetes. 
Thus, we examined the effect of defined spondyloarthritis diagnosis per se, not of chronic 
inflammation, on the age at CABG.  
The study results may not be generalized to patients with advanced renal failure or severe 
multi-organ complications, because those patients were not typically accepted for CABG at 
the Feiring Heart Clinic. 
 
5.1.3 Data collecting and processing
To assure the quality of the collected data, we used questionnaires with questions requiring 
“yes” or “no” or other predefined answers whenever applicable. For most self-reported 
measures, we used internationally validated instruments. The rheumatologic examination was 
performed by one investigator. Further, most laboratory tests were performed in batches in a 
standard, randomized, blinded manner.  
An important advantage of our method was the ability to collect surgical vascular and 
cardiac biopsies without increasing risk for the patients.  
The interpretation of a histological assessment is somewhat subjective, particularly in the 
distinction between submesothelial and adventitial infiltrates, and sometimes the distinction 
between large and multiple infiltrates. To minimize bias, the specimens were evaluated 
independently by at least 2 pathologists that were blinded to the patients’ medical histories. 
We documented the findings with photographs to facilitate interpretations. We plan to 
conduct immunohistochemical analyses that may contribute to the validation of our 
histochemical findings. These analyses may also delineate fine differences in the content and 
nature of lymphocytic and mononuclear cell infiltrates in different diagnostic categories e.g. 
SLE, spondyloarthritis, and RA; and thus reflect different mechanisms of inflammation in 
these disorders. Histochemical and immunohistochemical techniques have different strengths 
and weaknesses; therefore, a combination of these approaches is useful.  
The area of the examined specimens was not measured, and we cannot exclude slight 
variations in specimen size between patients; larger specimens offer a greater chance of 
finding pathologies. However, systematic errors are fairly unlikely, as the biopsies were 
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performed in the same way in both groups. In further analyses, we intend to use computerized 
immunohistochemical methods that allow area measurements.  
Although paraffin sections were used for histological analyses in most patients, frozen 
sections were used in eight patients. This probably did not substantially influence the results, 
because the important structures and MCIs were apparent in both types of sections. 
As mentioned in Chapter 1.5, we became aware that diagnosing vasculitis was quite 
subjective when based on the presence of inflammatory cells in the vessel walls. The 
interpretation is often influenced by clinical symptoms, and there is substantial variation 
among experts. Therefore, for the time being, we avoided classifications of the findings with 
regard to vasculitis, and instead, provided more objective, semi-quantitative descriptions of 
the findings. 
The occurrence of atherosclerotic lesions in the aorta is probably underestimated because 
the aortic specimens were taken from areas with less pronounced atherosclerosis for the 
patients’ safety.  
Calcifications in the intima of saphenous vein were considered atherosclerotic lesions, 
although they might represent a different pathology. Our judgment was in accordance with 
current criteria (89). 
We compared arteries of different sizes and structures. In future studies, it would be 
interesting to investigate whether the occurrence of atherosclerosis parallels the occurrence of 
inflammatory changes in vessels of similar caliber. 
It is impossible to collect all potentially important information in a study, due to e.g., 
feasibility and the limited general level of knowledge in the planning stages. In our study, 
many, but not all, cardiovascular risk and prognostic factors were recorded. The non-SpA 
group was less well characterized than groups where biological material was collected. This 
control group lacked information on CRP levels and former medical treatments. The current 
use of coxibs and NSAIDs was recorded in only one subgroup of these patients. In addition, 
the cardiovascular risk factors lacked detailed characterization; for example, we did not 
investigate proinflammatory properties of mediators of lipoprotein metabolism. These and 
other unrecognized factors might have influenced the premature need for CABG. 
 
5.2. Main results 
 
5.2.1 Inflammation and atherosclerosis in the aorta, saphenous vein, and 
IMA
In surgical specimens obtained during a CABG from patients with CAD, we detected 
inflammation in terms of inflammatory cell infiltrates in the thoracic aorta, saphenous vein, 
and IMA (Figure 10). Because acute inflammatory infiltrates occurred only in one specimen 
(aortic adventitia), we primarily focused on chronic, mononuclear cell infiltrates (MCIs), 
which occurred surprisingly frequently. MCIs were found within and outside atherosclerotic 
lesions. The latter, which were more common, were localised in the media and adventitia. The 
occurrences of MCIs in the vascular media and/or adventitia followed the same pattern as the 
occurrences of atherosclerotic lesions: most occurred in the aorta, fewer in the saphenous 
vein, and the least in the IMA. The pattern of atherosclerotic lesion occurrence in the 
respective vessels was in accordance with common knowledge and trends observed in other 
studies (77;79;80;91-94). The true occurrence of aortic atherosclerotic lesions is likely to be 
higher than that reported here, because the aortic specimens were specifically taken from 
areas with less pronounced macroscopic signs of atherosclerosis (see Chapter 3.2). 
In the aorta and saphenous vein, atherosclerotic lesions were slightly more frequent in 
patients with IRD than in those without IRD (21% vs. 14% in the aorta and 5% vs. 0% in the 
saphenous vein), but the differences were not statistically significant. No atherosclerotic 
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lesions were found in the IMA in any group. Inflamed atherosclerotic lesions, found only in 
the aorta, occurred at similar frequencies in both groups. However, we cannot rule out an 
underestimation of differences between the groups in frequency and characteristics of 
atherosclerotic lesions, because the total number of observed atherosclerotic lesions was 
small. Moreover, the lack of significant differences may be due, in part, to the similar 
severities of CAD; all patients were selected for CABG according to the same clinical criteria. 
MCIs outside atherosclerotic lesions occurred both in IRD and non-IRD patients. These 
MCIs were subclinical in all cases and consisted predominantly of lymphocytes. Except for 
the presence of giant cells in one adventitial specimen, we did not find any other characteristic 
signs of vasculitis in any patient (Papers I and II). 
In the aorta, we distinguished between MCIs localized diffusely in the vessel wall and those 
adjacent to the epicardial mesothelium. The latter might represent a normal phenomenon or 
might be related to an epicardial disease. Submesothelial MCIs occurred in half the patients, 
with similar frequencies in IRD and non-IRD groups (Figure 11). The submesothelial MCIs 
often colocalized with fibrosis (Paper I). Gross signs of epicardial fibrosis are commonly 
observed during a CABG and might contribute to restricted epicardial circulation. However, 
the clinical importance of epicardial fibrosis is still unclear.   
Adventitial MCIs in the aorta were more common in the IRD than the non-IRD group (47% 
vs. 20%, odds ratio=3.6, p=0.002). IRD patients also had greater sizes and numbers of MCIs. 
Aortic adventitial MCIs were found in almost all the rheumatic diseases; they were especially 
large and frequent in GCA/polymyalgia rheumatica and spondyloarthritis subgroups, diseases 
that are typically complicated with aortic involvement (31;95). MCIs in the aortic media only 
occurred in the IRD group (in 10%), and were especially frequent in patients with aortic 
aneurysms. They were present only in patients that also had aortic adventitial MCIs. In theory, 
MCIs spreading from the adventitia into the media may represent a more advanced stage of 
vascular injury than MCIs localized in only the adventitia.  
The extent and size of aortic adventitial MCIs were independently related to current 
smoking. Smoking is linked to inflammation in the lungs and joints, trombangiitis obliterans, 
and inflammatory aortic aneurysms (96). In theory, the harmful cardiovascular effects of 
smoking might also be related to enhanced vascular inflammation (Paper I).  
The frequencies of medial and/or adventitial MCIs in the saphenous vein or the IMA were 
not related to either IRD comorbidity or smoking status (Paper II). This could stem from a 
type 2 error due to the low frequency of MCIs or from the inherent resistance of these vessels 
to systemic cardiovascular risk factors. In a recent study, the IMA seemed to be resistant to 
atherosclerosis in patients with renal failure (97).  
Patients treated with systemic glucocorticosteroids, methotrexate, or TNF alpha inhibitors 
had a tendency (though statistically insignificant) to less pronounced adventitial inflammation 
in the aorta. This may reflect the effects of these drugs on vascular inflammation and should 
be investigated in further studies (Paper I).  
The clinical significance of the observed chronic inflammation in the vascular media and 
adventitia is not known, and may be different in the different vessels. It may be independent 
of or secondary to atherosclerosis, but it may also reflect an inflammatory process that 
induces plaque formation or instability (98-101). The fact that we did not find atherosclerotic 
lesions in all patients with subintimal MCIs, and vice versa, could not rule out a possible 
causal role of chronic vascular inflammation in atherosclerosis. The atherosclerotic lesions 
may evolve from vascular inflammation over time, and only in certain circumstances. 
Atherosclerotic lesions may represent a late stage of a process that is triggered or enhanced by 
subintimal inflammation (similarly to calcifications that evolve only in some cases of 
pulmonary tuberculosis). Nevertheless, the inflammation may be resolved at the end-stage. In 
addition, we could not rule out the possibility that atherosclerotic lesions or subintimal 
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inflammation existed in an area near the place the specimens were obtained (especially since 
the specimens were taken from less diseased areas). The low power of this study prevented 
determinations of clear associations between the co-existence of subintimal MCIs and 
inflamed and stable atherosclerotic plaques.  
Chronic vascular inflammation may contribute to the pathogenesis of atherosclerosis and 
confer high cardiovascular risk in smokers and individuals with IRD. The inherent resistance 
of some vessels to inflammation may influence the susceptibility to stenosis, and therefore 
their suitability as grafts. In addition, vascular inflammation may lower vessel wall resistance, 
and therefore contribute to the higher risk of aortic aneurysms in IRD (54;95;102-104) (Paper 
I). 
The cause of chronic vascular inflammation is unknown. Inflammation might be triggered 
by systemic inflammatory mediators, pressure, chemical substances, infections, or 
autoantigens (e.g., oxidized low density lipoproteins, heat shock proteins, or citrullinated 
proteins) (105;106). The development of atherosclerosis may depend both on systemic factors 
(e.g., traditional cardiovascular risk factors, dysregulation of the immune system, infection, or 
decreased number or function of endothelial progenitor cells) and on local vascular properties, 
including the biochemical composition of the vessel wall (e.g., the content of different 
proteoglycans), the presence and characteristics of the immunoreactive cells, neurohumoral 
regulation, or microcirculation (107-115). Both the intima and the deeper vascular layers may 
play a substantial role in plaque formation (100;116-119). We note that adventitial MCIs were 
often localized around the vasa vasorum (Paper I). Microvascular injury with increased 
endothelial permeability plays an important role in various rheumatic manifestations, 
including synovitis, and may be involved in the pathogenesis of atherosclerosis (116;120-
125).  
The adventitia consists predominantly of fatty tissue. The proinflammatory effects of 
adipose tissue are well recognized, as are the contributions of lipid metabolism and obesity to 
cardiovascular risk. Hypothetically, the observed high occurrence of MCIs in the perivascular 
and adventitial fat may be a sign of generalized adipose tissue dysfunction and inflammation. 
The fat related to blood vessels may play a particular role in atherogenesis (109;113;126;127).  
Vascular inflammation, e.g., in primary vasculitides, may occur in patchy patterns. We 
examined very small aortic specimens that were not selected by gross signs of inflammation. 
On the contrary, they were removed from less diseased areas for safety. Thus, aortic 
inflammation may be more common than shown by our results. 
Higuchi et al. demonstrated that the number of lymphocytes in the adventitia of coronary 
arteries was related to the presence of ruptured atherosclerotic plaques in the same part of the 
vessel. That suggested that adventitial inflammation may contribute to plaque instability (98). 
In our study, inflamed atherosclerotic lesions were associated with the size of adventitial 
MCIs. However, the association lost statistical significance after adjustment for possible 
confounders. Moreover, the presence of MCIs in the inner adventitia was not associated with 
the presence of acute coronary syndrome.  
The tools for detecting aortic inflammation are limited. Our sampling method allowed 
diagnosis in patients undergoing CABG, a relatively common surgery, without increasing 
perioperative risk. Peroperative macroscopic examination was useful for predicting aortic 
adventitial inflammation, but not for predicting MCIs in the saphenous vein and the IMA.  
Infiltration of the vessel wall by inflammatory cells is one of the criteria for the histological 
diagnosis of vasculitis. However, there is no defined cut-off for the size or localization of the 
infiltrates. For example, inflamed atherosclerotic plaques or rare inflammatory cells in the 
aortic wall are generally not classified as vasculitis. Therefore, additional criteria are needed 
for distinguishing between vasculitis and atherosclerosis with inflammation. Another 
approach is to consider atherosclerosis as an inflammatory process, a low-grade vasculitis. 
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Due to general uncertainty and disparities in interpretations of the histological criteria of 
vasculitis, we preferred to present our data in a descriptive form. 
Intimal thickening with calcifications and medial hyperplasia with fibrosis are usually 
considered to be a result of arterial pressure on a venous graft (“arterialization” of the vein). 
Like Milroy et al., we observed those signs in native saphenous veins (128). The graft patency 
might be related to preexisting pathologies in the conduit (128;129). 
Additional studies are needed to shed light on the role of subclinical vascular inflammation 
in the development of vascular pathologies, especially the formation and instability of 
atherosclerotic lesions and aneurysms. Elucidation of the causes of cardiovascular disease, the 
number one global cause of death, may have implications for its prevention and treatment. 
Chronic vascular inflammation may hypothetically be reduced with anti-infectious or 
immunomodulatory treatments, such as antirheumatic drugs, or statins (130). 
 
Figure 11. Mononuclear cell infiltrates (MCIs) in the aorta 
 
We observed a high occurrence of MCIs in the inner adventitia, localized diffusely in the 
connective tissue, and/or around the vasa vasorum. Adventitial MCIs were more frequent and 
extensive in IRD than in non-IRD patients. MCIs in the media were observed only in IRD 
patients. MCIs along the mesothelium (epicardial MCIs) were common in both IRD and non-
IRD patients. Atherosclerotic lesions and inflamed atherosclerotic lesions occurred at similar 
frequencies in IRD and non-IRD patients. 
 
 
5.2.2 Premature coronary artery bypass surgery in spondyloarthritides 
At the time of a first CABG, patients with spondyloarthritis were, on average, 
approximately seven years younger than those without spondyloarthritis. The age at 
spondyloarthritis onset was positively correlated to the age at the first CABG. Half the 
patients with spondyloarthritis compared to 25% of control patients underwent a first CABG 
before the age of 60. 
Adventitial MCI 
MCI in an 
atherosclerotic plaque 
MCI in the media 
Epicardial MCI 
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Spondyloarthritis was a stronger independent predictor of early CABG than most of the 
traditional cardiovascular risk factors; only current cigarette smoking had a similar effect. At 
the time of a first CABG, the mean age of current smokers was approximately six years 
younger than that of non-smokers. However, former smoking was not associated with 
premature CABG, which underlines the importance of smoking cessation. Surprisingly, 
patients with hypertension underwent CABG at a later age than normotensive patients. This 
might be due to a better cardiovascular prophylaxis in hypertensive patients or to positive 
effects of antihypertensive therapy. Glucocorticosteroid users underwent a first CABG at a 
later age than non-users. This might reflect a protective cardiovascular effect of the drug or a 
late debut of conditions requiring glucocorticosteroid treatment. 
The SpA and non-SpA groups were expected to have similar severities of CAD, as the 
groups were selected for CABG according to the same clinical criteria. Compared to the non-
SpA group, the SpA group had a significantly lower mean number of significant coronary 
artery stenoses. However, other markers of the severity of CAD (NYHA class, left ventricle 
function, occurrence of left main coronary artery stenosis, and particularly, the occurrence and 
mean number of former myocardial infarctions) were more altered in the SpA compared to 
the non-SpA group, but the differences were not statistically significant. Thus, although the 
spondyloarthritis patients were significantly younger than the controls, they seemed to have 
similar severities of CAD. The discrepancy between severity of CAD and the occurrence of 
significant coronary stenoses observed in our study may indicate a different pathogenesis of 
CAD in patients with spondyloarthritis compared to the general population. For example, 
patients with spondyloarthritis might be more susceptible to plaque instability (also in non-
significant stenoses) and/or thromboembolism and/or to aortic inflammation spreading to 
coronary arteries and causing left main coronary stenosis. Alternatively, the discrepancy 
might be due to a type I error. 
The early need for a CABG may indicate that patients with spondyloarthritis have an earlier 
onset of severe CAD than in the general population. This might be caused by vasculitis and/or 
accelerated atherothrombosis (131). As premature atherosclerosis occurs in various 
inflammatory diseases, the systemic inflammation might enhance atherothrombosis also in 
spondyloarthritides. We demonstrated in Paper I that patients with CAD and spondyloarthritis 
frequently had subclinical aortic inflammation. In theory, vascular inflammation might cause 
vascular stenosis and/or contribute to the development of atherosclerotic lesions. Thus, 
antirheumatic treatment could be useful for reducing cardiovascular morbidity in 
spondyloarthritis.  
Although the age difference between the groups could not be explained by differences in 
the traditional risk factors or current medications, the role of these factors may not be ruled 
out definitively. The lack of observed relationships might be due to type 2 errors. Moreover, a 
life time burden of medications and cardiovascular risk factors, including those not recorded 
in our study, might influence the premature need of CABG in spondyloarthritis. 
 
5.2 Prospective for future studies 
Main questions to be addressed in further studies with our bio- and databank: 
 What are the features and causes of chronic vascular inflammatory infiltrates?  
 Does chronic vascular inflammation influence the risk for perioperative and late 
complications?  
 Why are some vessels more prone to inflammation than others? Are there differences in 
composition; e.g., in the characteristics of extracellular matrix or in the presence of 
immunoreactive cells? 
 Do patients with and without IRD have different risks for perioperative and late 
complications? 
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 Do patients with IRD have more inflammation in small vessels and in the heart than 
patients without IRD? 
 
Several projects are currently in progress. We have also planned to collect vascular 
specimens from a larger patient population. 
 
6. Conclusions and clinical implications 
Conclusions
 It was possible to detect aortic inflammation in tissue specimens obtained in a CABG.  
 IRD patients had similar occurrence of inflamed atherosclerotic lesions and epicardial 
MCIs as non-IRD patients, but a significantly higher occurrence and extent of medial and 
adventitial MCIs in aortic specimens. Acute inflammatory cell infiltrate was observed 
only in 1 patient, in the aortic adventitia. 
 MCIs outside of atherosclerotic lesions, in the media or adventitia, occurred most 
frequently in the thoracic aorta, less frequently in the saphenous vein, and least frequently 
in the IMA; these frequencies paralleled susceptibilities of the vessels to atherosclerosis.  
 IRD and current cigarette smoking were independent predictors of MCIs in non-
atherosclerotic regions of the aorta, but not the saphenous vein or the IMA (i.e., vessels 
with lower frequencies of atherosclerosis and inflammation).  
 At the time of a first CABG, patients with spondyloarthritis were, on average, 7 years 
younger than patients without spondyloarthritis. Spondyloarthritis was a stronger 
independent predictor of early CABG than most traditional cardiovascular risk factors.  
 We have established a unique data- and biobank for future research. 
Clinical implications 
Clinicians should realize the opportunity of diagnosing aortitis in patients referred for a 
CABG. Inflammation in the vascular media and adventitia might play a role in the early 
pathogenesis of cardiovascular disease, in particular in atherosclerosis and aneurysms. If true, 
prophylaxis or treatment of vascular inflammation might reduce cardiovascular risk. 
Spondyloarthritis might be associated with premature CAD; therefore, these patients might 
require effective cardiovascular prophylaxis, treatment, and follow-up.  
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